Ethical Dilemma with Stakeholders

Hour-by-Hour Action Plan for the CEO:

First 24 Hours: Data Verification and Strategic Planning

Hours 0–2: Confirm Findings with Internal Research Team

• Action: Convene an emergency meeting with the research team to validate the data. Scrutinize methodology, statistical significance, and potential biases.
• Why: Ensure the findings are accurate and not a false positive. This step is critical to avoid acting on erroneous data.

Hours 2–4: Legal and Regulatory Consultation

• Action: Meet with the legal team and external regulatory counsel. Clarify timelines: Is the 6-month period for label updates, or is immediate adverse event reporting required (e.g., FDA’s 15-day rule for serious/unexpected events)?
• Why: Expedite initial regulatory notification to avoid non-compliance penalties. Legal must confirm if immediate action is mandated.

Hours 4–6: Engage Medical and Regulatory Leaders

• Action: Collaborate with the Chief Medical Officer (CMO) and regulatory affairs to draft a "Dear Healthcare Provider" letter and plan label updates. Identify interim measures (e.g., patient monitoring protocols).
• Why: Proactive communication mitigates patient harm and demonstrates regulatory diligence.

Hours 6–8: Financial Impact Assessment

• Action: Work with the CFO and Investor Relations (IR) to model financial scenarios: 40% stock drop, litigation risks, insurance, and revenue loss.
• Why: Prepare stakeholders for short-term financial pain while emphasizing long-term trust preservation.

Hours 8–10: PR and Communications Planning

• Action: Develop messaging for patients, HCPs, regulators, investors, and employees. Draft press releases, FAQs, and internal memos.
• Why: Unified messaging prevents misinformation and maintains trust.

Hours 10–12: Pre-Brief Key Board Members

• Action: Call dissenting board members individually. Present data, legal risks, and ethical imperatives. Highlight long-term reputational/financial risks of delay.
• Why: Align the board by addressing concerns about liability and shareholder value.

Hours 12–24: Prepare Board Materials and Earnings Call Script

• Action: Finalize board presentation (options, recommendations, risks) and earnings call script with IR and legal.
• Why: Ensure alignment across leadership and compliance with disclosure laws (e.g., SEC materiality rules).

---

Next 24 Hours: Execution and Communication

Hours 24–26: Board Meeting

• Action: Present findings, legal advice, and recommend immediate disclosure. Emphasize ethical duty and regulatory compliance. Call for a vote if necessary.
• Why: Collective board approval strengthens the decision, but CEO must act decisively if dissent persists.

Hours 26–28: Finalize Decision and Regulatory Filings

• Action: File preliminary adverse event reports with global regulators. Begin label update process.
• Why: Demonstrates compliance and prioritizes patient safety.

Hours 28–30: External Communications Launch

• Action: Issue press release, update website, and distribute provider/patient notifications. Activate PR crisis team.
• Why: Transparency reduces panic and positions the company as responsible.

Hours 30–36: Internal Communications

• Action: Host all-hands meeting or send CEO video/email explaining the situation, actions taken, and values upheld.
• Why: Maintain employee trust and prevent leaks or morale issues.

Hours 36–48: Earnings Call Preparation

• Action: Rehearse script with IR and legal. Stress transparency, patient safety, and long-term commitment.
• Why: Investors value honesty; downplaying the issue risks lawsuits and regulatory wrath.

---

Key Considerations and Rationale

1. Patient Safety and Ethics: Immediate action aligns with the Hippocratic oath and mitigates harm. Delaying risks lives and amplifies legal exposure.
2. Legal Compliance: Proactive reporting avoids punitive fines and criminal charges. SEC requires disclosure of material risks.
3. Financial Impact: A 40% stock drop is severe, but hiding the issue could cause bankruptcy if lawsuits/penalties follow.
4. Reputation: Transparency builds long-term trust with patients, regulators, and investors.
5. Board Dynamics: CEO must lead with data and ethics, even if dissent exists. Fiduciary duty includes avoiding catastrophic legal/PR risks.

Final Step (72 Hours): Earnings Call

• Disclose the issue candidly, outline mitigation steps, and emphasize patient safety. This honesty, while painful, positions the company for recovery and accountability.

By prioritizing ethics and compliance, the CEO safeguards the company’s long-term viability despite short-term financial pain.